Drugs / [225Ac]-FPI-1966
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05363605 | Apr 2022 → Sep 2023 | breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +4 | Fusion Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225Ac]-FPI-1966 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363605 ↗ |
| Modality | Other / unclassified | “[225Ac]-FPI-1966 is a targeted alpha therapeutic” NCT05363605 ↗ |